Medical Cannabis for the Treatment of Fibromyalgia

George Habib, MD, MPH; Suheil Artul, MD


J Clin Rheumatol. 2018;24(5):255-258. 

In This Article


Thirty patients were identified. One patient could not be contacted. Two patients had cancer, and 1 patient had inflammatory joint disease. Thus, 26 patients were included in the study. Nineteen patients (~73%) were females, and the mean age of the study group was 37.8 ± 7.6 years. The mean duration of a fibromyalgia diagnosis was 4.3 ± 2.64 years. The mean dose of MC was 26 ± 8.3 g per month, and the mean duration of treatment was 10.4 ± 11.3 months, with a median duration of 3 months. No patient ceased MC treatment.

Table 1 summarizes the demographic and clinical parameters of the patients. All the patients smoked or inhaled MC. One of the 26 patients used a combination of smoking and oral oil drops. Table 2 summarizes the mean score for each item in the FIQR before and after MC treatment. Table 3 summarizes the various medications patients took in the 2 months prior to MC treatment and in the 2 months under MC treatment. In the study group, 13 patients (50%) ceased taking any medication other than MC. Twelve patients (~46%) reduced the dose/number of mediations by at least 50% as compared with the dose/number of mediations prior to MC treatment. Table 4 summarizes the adverse effects of MC treatment reported by the patients.